Test gel QTORIN for adults with pachyonychia congenita
Part of Genetic & congenital, Skin clinical trials.
This Phase 3 study tests the safety and how the body absorbs (pharmacokinetics) of a rapamycin gel called QTORIN 3.9% in adults with pachyonychia congenita. It may help determine whether this gel is safe and works for people with this rare skin nail condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the earlier PALV-05 (VAPAUS) study
- You can and will use birth control as required by the study
- You are not pregnant and not breastfeeding
- You do not use sirolimus or any sirolimus-type medicine (including creams or gels)
- You do not have other serious medical problems that could interfere with safety or results
- You have not had—or do not plan—procedures or treatments that the study doctor thinks could affect safety or the measurements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
This trial tests a topical gel (a cream you apply to skin) containing sirolimus to treat angiokeratomas, which are small growths on the skin. The goal is to see if this treatment is safe and effective.
This early-stage study tests how two experimental medicines (povorcitinib by mouth and ruxolitinib cream on skin) work in healthy volunteers. Researchers will measure how these drugs move through your body and affect your skin to learn if they're safe and effective.
This trial tests a rapamycin cream to see if it helps make port-wine stain treatment work better. It is for children 10 or younger who are already planning to have laser therapy.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This trial tests a new capsule, TQH3906, for people with active psoriatic arthritis who haven't had success with other treatments. It aims to see if the drug is safe and works well for joint and skin symptoms.
Hear when a new Pachyonychia Congenita trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.